Drug Patent List
First Filer Exclusivity TimelineNew
Newsletter
Weekly Digest

Pharsight

Jiangsu Hengrui Med Drug Patent Portfolio

Jiangsu Hengrui Med's Family Patents


Family Patents





Clinical Trials

Recent Clinical Trials by Jiangsu Hengrui Med:

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer Jiangsu HengRui Medicine Co., Ltd. NA RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2
A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors Jiangsu HengRui Medicine Co., Ltd. NA RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2
SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial Jiangsu HengRui Medicine Co., Ltd. NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3
Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Jiangsu HengRui Medicine Co., Ltd. NA RECRUITING
(Aug 1, 2026)
PHASE1
A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer Jiangsu HengRui Medicine Co., Ltd. NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3
FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy. Jiangsu HengRui Medicine Co., Ltd. NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE3
A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients Jiangsu HengRui Medicine Co., Ltd. NA RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2
Drug-durg Interaction of SHR3680 With Digoxin, Rosuvastatin Calcium and Metformin Hydrochloride Jiangsu HengRui Medicine Co., Ltd. NA COMPLETED
(Jun 1, 2026)
PHASE1
A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations Jiangsu HengRui Medicine Co., Ltd. NA COMPLETED
(Jun 1, 2026)
PHASE3
Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer Jiangsu HengRui Medicine Co., Ltd. NA COMPLETED
(Jun 1, 2026)
PHASE1
A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer Jiangsu HengRui Medicine Co., Ltd. NA RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2
A Trial of Remimazolam for Intraoperative Sedation in Pediatric and Adolescent Patients Jiangsu HengRui Medicine Co., Ltd. NA COMPLETED
(Jun 1, 2026)
PHASE2, PHASE3
A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor Jiangsu HengRui Medicine Co., Ltd. NA RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2
A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer Jiangsu HengRui Medicine Co., Ltd. NA RECRUITING
(May 1, 2026)
PHASE3
A Study of SHR-A1811 in Subjects With Ovarian Cancer Jiangsu HengRui Medicine Co., Ltd. NA RECRUITING
(Apr 1, 2026)
PHASE3
A Study of Bupivacaine Liposome Injection in the Treatment of Pain After Thoracoscopic Surgery Jiangsu HengRui Medicine Co., Ltd. NA RECRUITING
(Mar 1, 2026)
PHASE2


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List